Federal Register / Vol. 73, No. 35 / Thursday, February 21, 2008 / Notices 9581 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Regulation of Adaptive 

Immunity by the Innate Immune System. 

Date: March 13, 2008. 

Time: 1:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6700B 

Rockledge Drive, MSC 3136, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Mercy R. Prabhudas, PhD, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

NIAID/NIH/DHHS, 6700B Rockledge Drive, 

MSC 7616, Bethesda, MD 20892–7616, 301–

451–2615, mp457n@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: February 13, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–773 Filed 2–20–08; 8:45 am] 

BILLING CODE: 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; SWAN. 

Date: March 4, 2008. 

Time: 2 p.m. to 6 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 7201 

Wisconsin Avenue, Suite 2C212, Bethesda, 

MD 20814 (Telephone Conference Call). 

Contact Person: Alicja L. Markowska, PhD, 

DSC, National Institute on Aging, 7201 

Wisconsin Avenue, Suite 2C212, Bethesda, 

MD 20892, 301–496–9666, 

markowsa@nia.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: February 13, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–774 Filed 2–20–08: 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

License: Development and 

Commercialization of Therapeutic 

Products for Breast Cancer 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: This notice, in accordance 

with 35 U.S.C. 209(c)(1) and 37 CFR 

Part 404.7(a)(1)(i), announces that the 

Department of Health and Human 

Services is contemplating the grant of an 

exclusive license to practice the 

inventions embodied in U.S. Patent 

Application No. 09/693,600 filed 

October 20, 2000 entitled ‘‘Method and 

Composition for Enhancing Immune 

Response’’ [E–037–2001/1–US–01]; 

Japanese Patent Application No. 2002–

555834 filed October 22, 2001 entitled 

‘‘Method and Composition for 

Enhancing Immune Response’’ [E–037–

2001/1–JP–03]; and European Patent 

Application No. 01989341.1 filed 

October 22, 2001 entitled ‘‘Method and 

Composition for Enhancing Immune 

Response’’ [E–037–2001/1–EP–04]; to 

ODC Therapy, Inc. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to 

therapeutic applications for breast 

cancer patients expressing high levels of 

serum or plasma IgE. 

DATES: Only written comments and/or 

license applications which are received 

by the National Institutes of Health on 

or before April 21, 2008 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent and/or patent applications, 

inquiries, comments and other materials 

relating to the contemplated exclusive 

license should be directed to: Mojdeh 

Bahar, J.D., M.A., Technology Licensing 

Specialist, Office of Technology 

Transfer, National Institutes of Health, 

6011 Executive Boulevard, Suite 325, 

Rockville, MD. 20852–3804. Telephone: 

(301) 435–2950; Facsimile: (301) 402–

0220; E-mail: baharm@od.nih.gov. 

SUPPLEMENTARY INFORMATION: The 

invention relates to a method of 

inhibiting tumor growth which 

comprises the administration of an IL–

13 inhibitor. Additionally, the invention 

relates to a method and composition for 

enhancing an immune response in a 

subject by administering to a subject an 

inhibitor of IL–13 or an inhibitor of an 

NK–T cell. The method can be used to 

prevent growth of a tumor in a subject, 

e.g., to inhibit tumor recurrence or 

metastasis. The method can also be used 

to enhance a response to a vaccine in a 

subject. IL–13 is an interleukin which 

has potent immunomodulatory effects. 

It is primarily secreted by TH2 

lymphocytes. This invention relates to 

the discovery of a role for IL–13 in the 

down-regulation of tumor 

immunosurveillance. Using a mouse 

model in which tumors show a growthregression-recurrence pattern, the 

mechanisms for down-regulation of 

cytotoxic T lymphocyte-mediated tumor 

immunosurveillance was investigated. It 

was discovered that interleukin 4 

receptor (IL–4R) knockout mice, and 

downstream signal transducer and 

activator of transcription 6 (STAT6) 

knockout mice, but not IL–4 knockout 

mice, resisted tumor recurrence. Thus, 

IL–13, the only other cytokine that uses 

the IL–4R–STAT6 pathway, was 

discovered to have a role in the downregulation of tumor 

immunosurveillance. 

The prospective exclusive license will 

be royalty-bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR 404.7. The prospective 

exclusive license may be granted unless 

within sixty (60) days from the date of 

this published notice, the NIH receives 

written evidence and argument that 

establish that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR 404.7. 


pwalker on PROD1PC71 with NOTICES